Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Notes Payables (2022 - 2025)

Bioregenx's Notes Payables history spans 4 years, with the latest figure at $1.0 million for Q4 2025.

  • Quarterly results put Notes Payables at $1.0 million for Q4 2025, up 13.58% from a year ago — trailing twelve months through Dec 2025 was $1.0 million (up 13.58% YoY), and the annual figure for FY2025 was $1.0 million, up 13.58%.
  • Notes Payables for Q4 2025 was $1.0 million at Bioregenx, down from $1.0 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $1.0 million in Q3 2025 to a low of $12590.0 in Q1 2023.
  • The 4-year median for Notes Payables is $850813.0 (2024), against an average of $601093.6.
  • The sharpest move saw Notes Payables skyrocketed 6657.85% in 2024, then rose 3.69% in 2025.
  • Year by year, Notes Payables stood at $40970.0 in 2022, then skyrocketed by 816.97% to $375681.0 in 2023, then soared by 135.11% to $883271.0 in 2024, then grew by 13.58% to $1.0 million in 2025.
  • According to Business Quant data, Notes Payables over the past three periods came in at $1.0 million, $1.0 million, and $970117.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.